Jiangsu Hengrui Pharmaceuticals (01276): HRS9531 Injection Received Approval Notice for Clinical Trials of Drugs

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiary Fujian Shengdi Pharmaceuticals Co., Ltd. (hereinafter referred to as "the Company") has received the Approval Notice for Drug Clinical Trial of HRS9531 Injection issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), and will conduct clinical trials in the near future. HRS9531 Injection is a novel dual agonist targeting gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), with HRS9531 as the main active ingredient and possessing global independent intellectual property rights. Its application for marketing in the treatment of long-term weight management in adults was accepted by the NMPA in September 2025. For adolescents who are overweight or obese, HRS9531 can regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity by activating GIPR and GLP-1R in the body, thereby improving blood sugar levels and weight reduction. Currently, there are no similar drugs approved for marketing worldwide for this indication. In addition, clinical trials for various other indications such as type 2 diabetes, obesity with heart failure, obstructive sleep apnea, and obesity with polycystic ovary syndrome are also actively progressing. As of now, the total research and development investment in projects related to HRS9531 is approximately 632 million yuan (unaudited).